Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Nov 7;13(11):e0205034.
doi: 10.1371/journal.pone.0205034. eCollection 2018.

Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study

Usha Salagame  1   2 , Emily Banks  3   4 , Dianne L O'Connell  1   2   5 , Sam Egger  1 , Karen Canfell  1   2   6
Affiliations
Clinical Trial

Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study

Usha Salagame et al. PLoS One. .

Abstract

Breast cancer risk is increased with current Menopausal Hormone Therapy (MHT) use, with higher risks reported for ER+ (Estrogen Receptor positive), and ER+/PR+ (Estrogen and Progesterone Receptor positive) breast cancers than those of ER- and ER-/PR- status, respectively. There is limited evidence to suggest MHT use is associated with the specific subtype characterised as ER+/PR+/HER2- (Estrogen and Progesterone Receptor positive and Human Epidermal growth factor Receptor2 negative) status. This study aims to investigate the MHT-breast cancer relationship for breast cancer tumor receptor subtypes defined by ER expression alone, by ER and PR expression only and by joint expression of ER, PR, and HER2. Analyses compared 399 cancer registry-verified breast cancer cases with receptor status information and 324 cancer-free controls. We used multinomial logistic regression to estimate adjusted odds ratios (aORs) and 95% Confidence Intervals (CI) for current and past versus never MHT use, for subgroups defined by tumor receptor expression. Current, but not past, use of MHT was associated with an elevated risk of ER+ breast cancer (aOR = 2.04, 95%CI: 1.28-3.24) and ER+/PR+ breast cancer (aOR = 2.29, 1.41-3.72). Current MHT use was also associated with an elevated risk of the ER+/PR+/HER2- subtype (aOR = 2.30, 1.42-3.73). None of the other subtypes based on ER, ER/PR or ER/PR/HER2 expression were significantly associated with current MHT use in this analysis. Current, but not past, use of MHT increases the risk of breast cancer, with consistently higher risks reported for ER+ and ER+/PR+ subtypes and mounting evidence regarding the specific ER+/PR+/HER2- subtype. Our findings contribute to quantification of the effects of MHT, and support efforts to articulate the receptor-mediated mechanisms by which MHT increases the risk of breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist. KC is co-principal investigator of an investigator-initiated trial of cytology and primary HPV screening in Australia (Compass; ACTRN12613001207707 and NCT02328872), which is conducted and funded by the Victorian Cytology Service (VCS), a government-funded health promotion charity. VCS has received equipment and a funding contribution for the Compass trial from Roche Molecular Systems and Ventana USA. KC is also an investigator for Compass in New Zealand (Compass NZ; ACTRN12614000714684), which is conducted and funded by Diagnostic Medlab (DML), now Auckland District Health Board. DML received an equipment and funding contribution for the Compass trial from Roche Molecular Systems. However neither KC nor her institution on her behalf (Cancer Council NSW) receive direct or indirect funding from industry for Compass Australia or NZ or any other project. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Available and eligible cases and controls for the analysis of MHT and breast cancer risk by receptor subtype.
Fig 2
Fig 2. MHT use and invasive breast cancer risk by breast cancer hormone receptor (ER/PR) status.
Legend: p* = p-value is for the test of global null hypothesis that the OR estimates are equal to one (i.e their reference group OR). Breast cancers with ER-/PR+ status (n = 6) were excluded from the analyses. All odds ratios were adjusted for age at index date, BMI, parity cross-classified by age at first birth, time since menopause, family history of breast cancer, place of residence, socioeconomic disadvantage quintile, oral contraceptive use, history of breast screening and alcohol consumption.
Fig 3
Fig 3. MHT use and invasive breast cancer risk for subtypes based on ER, PR, and HER2 status.
P* = p-value is for the test of global null hypothesis that the OR estimates are equal to one (i.e their reference group OR). All odds ratios were adjusted for age at index date, BMI, parity cross-classified by age at first birth, time since menopause, family history of breast cancer, place of residence, socioeconomic disadvantage quintile, oral contraceptive use, breast screening history and alcohol consumption.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136: E359–E386. 10.1002/ijc.29210 - DOI - PubMed
    1. Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer. Tumori 2008; 94: 370–383. - PubMed
    1. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13: 1141–1151. 10.1016/S1470-2045(12)70425-4 - DOI - PMC - PubMed
    1. Anderson KN, Schwab RB, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat. 2014;144: 1–10. 10.1007/s10549-014-2852-7 - DOI - PMC - PubMed
    1. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk Factors for Breast Cancer according to Estrogen and Progesterone Receptor Status. J Natl Cancer Inst. 2004; 96: 218–228. - PubMed

Publication types